GrifoisGRFS
Market Cap: $5.98B
About: As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Employees: 23,737
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
298% more call options, than puts
Call options by funds: $24.8M | Put options by funds: $6.24M
50% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]
49% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 35
3.49% more ownership
Funds ownership: 51.84% [Q1] → 55.33% (+3.49%) [Q2]
1% more capital invested
Capital invested by funds: $905M [Q1] → $911M (+$5.57M) [Q2]
0% more funds holding
Funds holding: 126 [Q1] → 126 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
Research analyst outlook
We haven’t received any recent analyst ratings for GRFS.
Financial journalist opinion
Based on 15 articles about GRFS published over the past 30 days